Applied Filters
Pharmaceutical trademarks: The smooth path to registration
Pharmaceutical trademark owners in Australia should carefully select and register their marks to minimise potential problems associated with including INNs or INN stems, as Geordie Oldfield of Dennemeyer explains.
Interpol: clamping down on pharma crime
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports.
The devil in the judicial detail
The judiciary system for the new Unified Patent Court has been the subject of much discussion. As part of a regular column, Paul England, senior associate at law firm Taylor Wessing and who chaired a recent discussion between a panel of experts, examines the issue.
Tightening the customs net
Tax avoidance involving the import of undeclared trademarked items has led the Mexican customs authorities to change the regulations governing the information that must be submitted, as Daniel Sánchez and Víctor Ramírez of Olivares describe.
Brazil focus: Protecting plant varieties—without IP law
There is increasing demand for plant variety protection in Brazil. Renata Campello Afonso of Luiz Leonardos & Advogados reports.
SPCs: The semantics of protection
Despite the SPC Regulation having been in existence for decades, applicants are still left to navigate uncertain waters on issues of fundamental importance when it comes to ‘combination’ therapies, as Michael Pears of Potter Clarkson reports.
TPP: Coming into line
As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports.
Gilead: Treating the seven million
Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.
IP in Australia: major changes in store
February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector.
Preview: Practical Law’s Life Sciences Forum
LSIPR takes a look at what the Practical Law Life Sciences Forum, due to take place on June 25, has to offer.
